Peter F Rambau1,2, Máire A Duggan2, Prafull Ghatage3, Khadija Warfa4, Helen Steed5, Renee Perrier6, Linda E Kelemen7,8, Martin Köbel2. 1. Department of Pathology, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania. 2. Department of Pathology and Laboratory Medicine, Calgary Laboratory Services/Alberta Health Services and University of Calgary, Calgary, AB, Canada. 3. Department of Gynecological Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. 4. Department of Obstetrics and Gynaecology, Aga Khan University Hospital, Nairobi, Kenya. 5. Department of Obstetrics and Gynecology, University of Alberta, Edmonton, AB, Canada. 6. Department of Medical Genetics, University of Calgary, Calgary, AB, Canada. 7. Department of Public Health Sciences, College of Medicine, Charleston, SC, USA. 8. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Abstract
AIMS: Lynch syndrome screening in ovarian carcinoma is controversial. The aim of this study was to assess the frequency of deficient mismatch repair (dMMR) protein in a retrospective cohort enriched for non-high-grade serous carcinomas and its association with outcome within histological types. METHODS AND RESULTS: Tissue microarrays representing 612 ovarian carcinomas were tested for mismatch repair proteins (MLH1, PMS2, MSH2, and MSH6) by immunohistochemistry. dMMR was detected in 13.8% of endometrioid and 2.4% of clear cell carcinomas, but not in other histological types. Within endometrioid carcinomas, 11 of 25 dMMR cases showed abnormal MLH1/PMS2, 10 cases showed abnormal MSH2/MSH6, and four cases showed only abnormal MSH6, indicating that at least 7.7% of endometrioid carcinomas have dMMR probably related to Lynch syndrome. The four dMMR clear cell carcinomas showed abnormal MSH2/MSH6 in three cases and only abnormal MSH6 in one case, all probably related to Lynch syndrome. Within endometrioid carcinomas, dMMR was significantly associated with age <50 years, synchronous endometrial endometrioid carcinoma, a higher CA125 level at diagnosis, higher FIGO grade, absence of ARID1A, and at least 20 CD8-positive intraepithelial lymphocytes per high-power field, but was not associated with cancer-specific death. Age <50 years, higher CA125 levels at diagnosis and at least 20 CD8-positive intraepithelial lymphocytes per high-power field remained significant after adjustment for multiple testing, but their sensitivity for identifying dMMR remained insufficient. CONCLUSION: Our data support the policy of histotype-specific Lynch syndrome screening in ovarian carcinoma confined to endometrioid and clear cell carcinomas.
AIMS: Lynch syndrome screening in ovarian carcinoma is controversial. The aim of this study was to assess the frequency of deficient mismatch repair (dMMR) protein in a retrospective cohort enriched for non-high-grade serous carcinomas and its association with outcome within histological types. METHODS AND RESULTS: Tissue microarrays representing 612 ovarian carcinomas were tested for mismatch repair proteins (MLH1, PMS2, MSH2, and MSH6) by immunohistochemistry. dMMR was detected in 13.8% of endometrioid and 2.4% of clear cell carcinomas, but not in other histological types. Within endometrioid carcinomas, 11 of 25 dMMR cases showed abnormal MLH1/PMS2, 10 cases showed abnormal MSH2/MSH6, and four cases showed only abnormal MSH6, indicating that at least 7.7% of endometrioid carcinomas have dMMR probably related to Lynch syndrome. The four dMMRclear cell carcinomas showed abnormal MSH2/MSH6 in three cases and only abnormal MSH6 in one case, all probably related to Lynch syndrome. Within endometrioid carcinomas, dMMR was significantly associated with age <50 years, synchronous endometrial endometrioid carcinoma, a higher CA125 level at diagnosis, higher FIGO grade, absence of ARID1A, and at least 20 CD8-positive intraepithelial lymphocytes per high-power field, but was not associated with cancer-specific death. Age <50 years, higher CA125 levels at diagnosis and at least 20 CD8-positive intraepithelial lymphocytes per high-power field remained significant after adjustment for multiple testing, but their sensitivity for identifying dMMR remained insufficient. CONCLUSION: Our data support the policy of histotype-specific Lynch syndrome screening in ovarian carcinoma confined to endometrioid and clear cell carcinomas.
Authors: Carlos Parra-Herran; Jordan Lerner-Ellis; Bin Xu; Sam Khalouei; Dina Bassiouny; Matthew Cesari; Nadia Ismiil; Sharon Nofech-Mozes Journal: Mod Pathol Date: 2017-08-04 Impact factor: 7.842
Authors: Martin Köbel; Li Luo; Xin Grevers; Sandra Lee; Angela Brooks-Wilson; C Blake Gilks; Nhu D Le; Linda S Cook Journal: Int J Gynecol Pathol Date: 2019-07 Impact factor: 2.762
Authors: Shama Virani; Glauco Baiocchi; David Bowtell; Citadel J Cabasag; Kathleen R Cho; Renée T Fortner; Keiichi Fujiwara; Jae-Weon Kim; Martin Köbel; Jean-Emmanuel Kurtz; Douglas A Levine; Usha Menon; Barbara M Norquist; Paul D P Pharoah; Anil K Sood; Shelley T Tworoger; Nicolas Wentzensen; Stephen J Chanock; Paul Brennan; Britton Trabert Journal: Carcinogenesis Date: 2021-06-21 Impact factor: 4.944
Authors: George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis M Giardiello Journal: Fam Cancer Date: 2021-01-11 Impact factor: 2.375
Authors: Ellen L Goode; Matthew S Block; Kimberly R Kalli; Robert A Vierkant; Wenqian Chen; Zachary C Fogarty; Aleksandra Gentry-Maharaj; Aleksandra Tołoczko; Alexander Hein; Aliecia L Bouligny; Allan Jensen; Ana Osorio; Andreas Hartkopf; Andy Ryan; Anita Chudecka-Głaz; Anthony M Magliocco; Arndt Hartmann; Audrey Y Jung; Bo Gao; Brenda Y Hernandez; Brooke L Fridley; Bryan M McCauley; Catherine J Kennedy; Chen Wang; Chloe Karpinskyj; Christiani B de Sousa; Daniel G Tiezzi; David L Wachter; Esther Herpel; Florin Andrei Taran; Francesmary Modugno; Gregg Nelson; Jan Lubiński; Janusz Menkiszak; Jennifer Alsop; Jenny Lester; Jesús García-Donas; Jill Nation; José Palacios; Joseph H Rothstein; Joseph L Kelley; Jurandyr M de Andrade; Luis Robles-Díaz; Maria P Intermaggio; Martin Widschwendter; Matthias W Beckmann; Matthias Ruebner; Mercedes Jimenez-Linan; Naveena Singh; Oleg Oszurek; Paul R Harnett; Peter F Rambau; Peter Sinn; Philipp Wagner; Prafull Ghatage; Raghwa Sharma; Robert P Edwards; Roberta B Ness; Sandra Orsulic; Sara Y Brucker; Sharon E Johnatty; Teri A Longacre; Eilber Ursula; Valerie McGuire; Weiva Sieh; Yanina Natanzon; Zheng Li; Alice S Whittemore; deFazio Anna; Annette Staebler; Beth Y Karlan; Blake Gilks; David D Bowtell; Estrid Høgdall; Francisco J Candido dos Reis; Helen Steed; Ian G Campbell; Jacek Gronwald; Javier Benítez; Jennifer M Koziak; Jenny Chang-Claude; Kirsten B Moysich; Linda E Kelemen; Linda S Cook; Marc T Goodman; María José García; Peter A Fasching; Stefan Kommoss; Suha Deen; Susanne K Kjaer; Usha Menon; James D Brenton; Paul DP Pharoah; Georgia Chenevix-Trench; David G Huntsman; Stacey J Winham; Martin Köbel; Susan J Ramus Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 33.006
Authors: Peter Rambau; Linda E Kelemen; Helen Steed; May Lynn Quan; Prafull Ghatage; Martin Köbel Journal: Int J Mol Sci Date: 2017-02-27 Impact factor: 5.923